Education
About Us
Working with TipRanks
Follow Us
Aerovate Therapeutics (AVTE)
NASDAQ:AVTE
AVTE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.25 - $25.58
Previous CloseN/A
Volume47.72K
Average Volume (3M)103.86K
Market Cap
$74.78M
Enterprise Value-$1.40M
Total Cash (Recent Filing)$33.75M
Total Debt (Recent Filing)$417.00K
Price to Earnings (P/E)―
Beta1.18
Next Earnings
May 19, 2025EPS Estimate
-0.27Next Dividend Ex-Date
Apr 25, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding28,985,020
10 Day Avg. Volume173,625
30 Day Avg. Volume103,856
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Aerovate Therapeutics News
PremiumCompany Announcements
Aerovate Announces Special Dividend Amid Jade Merger
PremiumCompany Announcements
Aerovate Therapeutics Announces Merger with Jade Biosciences
PremiumPre-Earnings
Is AVTE a Buy, Before Earnings?
PremiumCompany Announcements
Aerovate Therapeutics Reports Q3 Loss Amid Strategic Shift---
Ownership Overview
51.18% Insiders
4.89% Mutual Funds
0.26% Other Institutional Investors
38.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVTE FAQ
What was Aerovate Therapeutics’s price range in the past 12 months?
Aerovate Therapeutics lowest stock price was $1.25 and its highest was $25.58 in the past 12 months.
What is Aerovate Therapeutics’s market cap?
Aerovate Therapeutics’s market cap is $74.78M.
When is Aerovate Therapeutics’s upcoming earnings report date?
Aerovate Therapeutics’s upcoming earnings report date is May 19, 2025 which is in 36 days.
How were Aerovate Therapeutics’s earnings last quarter?
Aerovate Therapeutics released its earnings results on Mar 26, 2025. The company reported -$0.189 earnings per share for the quarter, missing the consensus estimate of -$0.188 by -$0.001.
Is Aerovate Therapeutics overvalued?
According to Wall Street analysts Aerovate Therapeutics’s price is currently Overvalued.
Does Aerovate Therapeutics pay dividends?
Aerovate Therapeutics pays a Notavailable dividend of $2.4 which represents an annual dividend yield of N/A. See more information on Aerovate Therapeutics dividends here
What is Aerovate Therapeutics’s EPS estimate?
Aerovate Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Aerovate Therapeutics have?
Aerovate Therapeutics has 28,985,020 shares outstanding.
What happened to Aerovate Therapeutics’s price movement after its last earnings report?
Aerovate Therapeutics reported an EPS of -$0.189 in its last earnings report, missing expectations of -$0.188. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aerovate Therapeutics?
Currently, no hedge funds are holding shares in AVTE
---
Aerovate Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-90.10%
12-Months-Change
Fundamentals
Return on Equity
-74.91%
Trailing 12-Months
Asset Growth
-36.95%
Trailing 12-Months
Company Description
Aerovate Therapeutics
Aerovate Therapeutics (AVTE) is a biotechnology company focused on developing innovative therapies for severe respiratory diseases. The company operates within the pharmaceutical and biotechnology sectors, specializing in the research and development of novel treatments aimed at addressing unmet medical needs in pulmonary arterial hypertension (PAH) and other serious conditions. Aerovate's core product pipeline includes AV-101, an inhaled dry powder formulation of imatinib, designed to improve the lives of patients suffering from PAH.
---
AVTE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
United Therapeutics
―
Pulmatrix
―
Mereo Biopharma Group Plc
―
Arcutis Biotherapeutics
―
Best Analysts Covering AVTE
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-86.55%
reiterated a buy rating 10 months ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -86.55% per trade.
---